Posted 1/2/2024, 6:18:00 PM
Eli Lilly's New Weight Loss Drug Zepbound Takes Off, Poised to Dominate Market
- Eli Lilly's new weight loss drug Zepbound prescriptions are soaring after recent FDA approval, poised to dominate the GLP-1 market in 2024 according to BMO
- Zepbound prescriptions jumped 192% week-over-week to 22,335 in its first full month on the market
- Rival Novo Nordisk saw prescriptions decline for its Wegovy and Ozempic GLP-1 drugs
- Zepbound's early traction compares very favorably to the initial months of other leading weight loss drugs
- BMO predicts Eli Lilly's GLP-1 franchise will "dominate the landscape" in 2024 based on tirzepatide's efficacy and tolerability